JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

Home・Aandelen Lijst・ADMA Biologics Inc
Search

ADMA Biologics Inc

Gesloten

SectorGezondheidszorg

10.5 2.74

Buy

Prijsupdate 1 mei 2026, 19:59 UTC

BuySell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

10.41

Max

10.56

Belangrijke statistieken

By Trading Economics

Inkomsten

13M

49M

Verkoop

4.9M

139M

K/W

Sectorgemiddelde

18.217

67.147

EPS

0.216

Winstmarge

35.483

Werknemers

640

EBITDA

14M

65M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+142.48% upside

Dividenden

By Dow Jones

Volgende Winsten

6 mei 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-1.3B

2.5B

Vorige openingsprijs

7.76

Vorige sluitingsprijs

10.5

Nieuwssentiment

By Acuity

58%

42%

299 / 347 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

N/A / 23.5406 Steun & Weerstand

ADMA Biologics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

4 mei 2026, 22:17 UTC

Winsten

Australia's Westpac Lifts Dividend as 1st Half Profit Rises 2.7%

DJ

Lezen

4 mei 2026, 23:47 UTC

Winsten

Grab Holdings 1Q Adj EBITDA $154.0M Vs. $106.0M >GRAB

DJ

Lezen

4 mei 2026, 23:45 UTC

Winsten

Grab Holdings 1Q Rev $955.0M Vs. $773.0M >GRAB

DJ

Lezen

4 mei 2026, 23:45 UTC

Winsten

Grab Holdings 1Q Net $120.0M Vs. Net $10.0M >GRAB

DJ

Lezen

4 mei 2026, 23:40 UTC

Marktinformatie

Gold Steady Amid Likely Technical Recovery -- Market Talk

DJ

Lezen

4 mei 2026, 22:44 UTC

Acquisities, Fusies, Overnames

Regis: Jim Beyer To Be Chief Executive of Combined Company

DJ

Lezen

4 mei 2026, 22:43 UTC

Acquisities, Fusies, Overnames

Regis: Russell Clark To Be Nonexecutive Chairman of Combined Company

DJ

Lezen

4 mei 2026, 22:42 UTC

Acquisities, Fusies, Overnames

Regis: Companies Expect to Realize Over A$500 Million in Corporate Tax Benefits

DJ

Lezen

4 mei 2026, 22:42 UTC

Acquisities, Fusies, Overnames

Regis: Combined Company to Have Strong, Debt-Free Balance Sheet; Significant Cash Generation

DJ

Lezen

4 mei 2026, 22:41 UTC

Acquisities, Fusies, Overnames

Regis: Combined Company to Have Annual Production of More Than 700,000 Oz

DJ

Lezen

4 mei 2026, 22:41 UTC

Acquisities, Fusies, Overnames

Regis: Pro Forma Market Capitalization About A$10.7 Billion

DJ

Lezen

4 mei 2026, 22:40 UTC

Acquisities, Fusies, Overnames

Regis: Shareholders to Own About 51% of Combined Company

DJ

Lezen

4 mei 2026, 22:40 UTC

Acquisities, Fusies, Overnames

Regis: Board Unanimously Endorsed, Supported Deal

DJ

Lezen

4 mei 2026, 22:40 UTC

Acquisities, Fusies, Overnames

Regis: Deal Unanimously Recommended by Vault Board

DJ

Lezen

4 mei 2026, 22:39 UTC

Acquisities, Fusies, Overnames

Regis: Vault Shareholders to Receive 0.6947 New Shares in Regis For Each Vault One Held

DJ

Lezen

4 mei 2026, 22:38 UTC

Acquisities, Fusies, Overnames

Regis Resources to Acquire All Ordinary Shares in Vault

DJ

Lezen

4 mei 2026, 22:38 UTC

Acquisities, Fusies, Overnames

Regis Resources, Vault Minerals Agree to Merger of Equals

DJ

Lezen

4 mei 2026, 22:37 UTC

Winsten
Acquisities, Fusies, Overnames

Palantir Beats Forecasts With $1.63 Billion Quarter as Sales Accelerate -- 2nd Update

DJ

Lezen

4 mei 2026, 22:26 UTC

Winsten
Acquisities, Fusies, Overnames

Palantir Beats Forecasts With $1.63 Billion Quarter as Sales Accelerate -- Update

DJ

Lezen

4 mei 2026, 22:02 UTC

Winsten

Australia's Westpac Lifts Dividend as 1H Profit Rises 2.7%

DJ

Lezen

4 mei 2026, 22:00 UTC

Marktinformatie

BOC's Macklem: Conditions To Dictate Fuel-Price Response -- Market Talk

DJ

Lezen

4 mei 2026, 21:52 UTC

Winsten

Westpac 1H Net Profit Ex-Notable Items A$3.48B Vs. A$3.46B>WBC.AU

DJ

Lezen

4 mei 2026, 21:50 UTC

Winsten

Westpac: Some Sectors More Affected Than Others>WBC.AU

DJ

Lezen

4 mei 2026, 21:50 UTC

Winsten

Westpac: Economic Impact of Middle East Conflict to Continue Through Year>WBC.AU

DJ

Lezen

4 mei 2026, 21:49 UTC

Winsten

Westpac 1H Provision for Expected Credit Losses A$4.68B Vs. A$4.58B>WBC.AU

DJ

Lezen

4 mei 2026, 21:44 UTC

Winsten

Westpac 1H Australia Lending Up 8% on Year>WBC.AU

DJ

Lezen

4 mei 2026, 21:44 UTC

Winsten

Westpac 1H Australia Business Lending Up 16% on Year>WBC.AU

DJ

Lezen

4 mei 2026, 21:43 UTC

Winsten

Westpac 1H Core Net Interest Margin 1.78% Vs. 1.80%>WBC.AU

DJ

Lezen

4 mei 2026, 21:41 UTC

Winsten

Westpac 1H Australian Home Lending Up 7% on Year Excluding RAMS Portfolio>WBC.AU

DJ

Lezen

4 mei 2026, 21:40 UTC

Winsten

Westpac 1H Credit Impairment Charge 10 Bps of Average Loans Vs. 6 Bps>WBC.AU

DJ

Lezen

Peer Vergelijking

Prijswijziging

ADMA Biologics Inc Prognose

Koersdoel

By TipRanks

142.48% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 25 USD  142.48%

Hoogste 30 USD

Laagste 21 USD

Gebaseerd op 3 Wall Street-analisten die 12-maands prijsdoelen bieden voor ADMA Biologics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

3 ratings

2

Buy

1

Hold

0

Sell

Gebaseerd op 3 analisten die aandelenratings hebben gegeven aan ADMA Biologics Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

N/A / 23.5406Steun & Weerstand

Korte Termijn

Very Strong Bearish Evidence

Recent bearish events outweigh bullish events.

Gemiddeld Termijn

Strong Bullish Evidence

All events are bullish.

Lange Termijn

Weak Bullish Evidence

There is one bullish event.

Sentiment

By Acuity

299 / 347 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over ADMA Biologics Inc

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

Andere aandelen uit de sector

JNJ

Johnson and Johnson

225.57

↑ +0.63%

UNH

UnitedHealth Group Inc

363.82

↓-1.87%

TMO

Thermo Fisher Scientific Inc

466.62

↑ +0.92%

ISRG

Intuitive Surgical Inc

451.55

↓-0.21%

ABT

Abbott Laboratories

87.15

↓-0.47%
help-icon Live chat